Zelquistinel in the Treatment of Major Depressive Disorder

Summary

The purpose of this study is to evaluate the efficacy at 1 day post initial oral dose of zelquistinel (AGN-241751) compared with placebo in participants with Major Depressive Disorder (MDD).

Timeline

Start

2018-06-13

Primary completion

2019-07-22

Completion

2019-08-21

Outcome

Missed primary endpoint

registry Comparison of each dose level change from baseline to placebo baseline yielded P values \>0.05 NCT03586427 ↗

Drugs

Indications